GEORGE BLAIR II: Open Payments
NPI 1588678973 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,401 in 56 payments from 9 companies in 2025. Trend: 2023 $933 · 2024 $1,845 · 2025 $1,401
Food & beverage: $1,292Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $445 |
| Janssen Pharmaceuticals, Inc | 10 | $256 |
| E.R. Squibb & Sons, L.L.C. | 11 | $236 |
| Otsuka America Pharmaceutical, Inc. | 7 | $143 |
| Vanda Pharmaceuticals Inc. | 5 | $107 |
| Alkermes, Inc. | 4 | $99 |
| Luye Pharma (USA) Ltd. | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
| Lundbeck LLC | 1 | $20 |
Products named: AUSTEDO XR, INVEGA SUSTENNA, ABILIFY ASIMTUFII, FANAPT, ARISTADA, COBENFY, UZEDY, ERZOFRI EXTENDED-RELEASE.
Industry payments across CA — which companies pay providers there.
